Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas

Japanese Journal of Clinical Oncology

Volumn 40, Issue 4, 2010, Pages 313-318

  Iwasa, Satoru ^a   Morizane, Chigusa ^a   Okusaka, Takuji ^a   Ueno, Hideki ^a   Ikeda, Masafumi ^b   Kondo, Shunsuke ^a   Tanaka, Tsutomu ^a,c   Nakachi, Kohei ^b   Mitsunaga, Shuichi ^b   Kojima, Yasushi ^b   Hagihara, Atsushi ^a   Hiraoka, Nobuyoshi ^d  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Chemotherapy; Cisplatin; Etoposide; Neuroendocrine carcinoma

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NEURON SPECIFIC ENOLASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GALLBLADDER CARCINOMA; GASTROINTESTINAL TOXICITY; HEPATOBILIARY SYSTEM CANCER; HEPATOBILIARY SYSTEM CARCINOMA; HUMAN; INOPERABLE CANCER; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER CARCINOMA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CARCINOMA; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SENSORY DYSFUNCTION; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; VATER PAPILLA CARCINOMA; BILIARY TRACT TUMOR; DISEASE FREE SURVIVAL; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; MORTALITY; PANCREAS TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CARCINOMA, NEUROENDOCRINE; CISPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 77951251193     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp173     Document Type: Article

References (26)

1. Doherty GM. Carcinoid tumors and the carcinoid syndrome. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 8th edn. Philadelphia, PA: Lippincott Williams & Wilkins, Inc. 2008;1721-40.
2. National Comprehensive Cancer Network (NCCN). Neuroendocrine Tumors 2008. http://www.nccn.org.
3. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on be half of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004;80:394-424.
4. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
5. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-5.
6. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101-7.
7. Solcia E, Capella C, Kloppel G, Heitz PU, Sobin LH, Rosai J. Endocrine tumours of the gastrointestinal tract. In: Solcia E, Kloppel G, Sobin LH, editors. World Health Organization International Histological Classification of Tumours. Histological Typing of Endocrine Tumours. 2nd edn. Berlin, Heidelberg, New York: Springer 2000;61-8.
8. DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization classification of tumours, pathology and genetics of tumours of endocrine organs. Lyon, France: IARC Press 2004.
9. Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007;97:162-9.
10. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685-90.
11. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-71.
12. Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 1998;43:422-7.
13. Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083-92.
14. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 2008;19:903-8.
15. Takubo K, Nakamura K, Sawabe M, Arai T, Esaki Y, Miyashita M, et al. Primary undifferentiated small cell carcinoma of the esophagus. Hum Pathol 1999;30:216-21.
16. Brenner B, Tang LH, Klimstra DS, Kelsen DP. Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol 2004;22: 2730-9.
17. Johnson BE, Whang-Peng J, Naylor SL, Zbar B, Brauch H, Lee E, et al. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J Natl Cancer Inst 1989;81:1223-8.
18. Wick MR, Weatherby R, Weiland LH. Small cell neuroendocrine carcinoma of the colon and rectum: clinical, histologic, and ultrastructural study and immunohistochemical comparison with cloacogenic carcinoma. Hum Pathol 1987;18:9-21.
19. Burke AB, Shekitka K, Sobin LH. Small cell carcinomas of the large intestine. Am J Clin Pathol 1991;95:315-21.
20. Ho KJ, Herrera GA, Jones JM, Alexander CB. Small cell carcinoma of the esophagus: evidence for a unified histogenesis. Hum Pathol 1984;15:460-8.
21. Maitra A, Tascilar M, Hruban RH, Offerhaus GJ, Albores-Saavedra J. Small cell carcinoma of the gallbladder: a clinicopathologic, immunohistochemical, and molecular pathology study of 12 cases. Am J Surg Pathol 2001;25:595-601.
22. Sarsfield P, Anthony PP. Small cell undifferentiated ('neuroendocrine') carcinoma of the colon. Histopathology 1990;16:357-63.
23. Brenner B, Shah MA, Gonen M, Klimstra DS, Shia J, Kelsen DP. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer 2004;90:1720-6.
24. Fellegara G, D'Adda T, Pilato FP, Froio E, Ampollini L, Rusca M, et al. Genetics of a combined lung small cell carcinoma and large cell neuroendocrine carcinoma with adenocarcinoma. Virchows Arch 2008;453:107-15.
25. Vortmeyer AO, Lubensky IA, Merino MJ, Wang CY, Pham T, Furth EE, et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst 1997;89:1448-53.
26. Motojima K, Furui J, Terada M, Shiogama T, Kohara N, Tsunoda T, et al. Small cell carcinoma of the pancreas and biliary tract. J Surg Oncol 1990;45:164-8.